Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda/Shire Clears Last Antimonopoly Hurdle – Shareholders Up Next

Executive Summary

European Commission gives an expected conditional regulatory approval for the acquisition of Shire by Takeda, removing the last potential antitrust hurdle to the deal, meaning that attention is now turning to the upcoming shareholders' meetings that would open the final path to the early January completion of the record-setting transaction.

You may also be interested in...



Takeda Offers Shire Asset Disposal To Assuage EC Merger Concerns

Takeda may have to shed a Shire late-stage pipeline asset to meet European anti-competition concerns around the companies' planned merger, although the process is not expected to derail the deal's timing. 

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: the prospects and plans for J&J’s pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda; and Moderna’s co-founder shares tips on innovation.

Ono, PD-1 Discoverer Settle Long-Running Patent Dispute

Japanese firm and key discoverer of immuno-oncology protein reach settlement of patent-related dispute that includes formation of new academic research fund. 

Topics

Related Companies

UsernamePublicRestriction

Register

SC124206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel